Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

<< Previous

Bullboard Posts

Next >>

Post by knoxton Mar 07, 2022 12:26pm

174 Views

Post# 34491024

Up date on news

Vaxil Bio Provides Update on Research Activities

07 Mar 202211:42 ET

11:42 AM EST, 03/07/2022 (MT Newswires) -- Vaxil Bio (VXL.V) on Monday provided an update on its research activities.

The company had previously reported therapeutic success of P-Esbp-DOX, a novel anti-cancer drug, when tested in vivo in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). Following the promising results of the in vivo study, Vaxil is implementing a screening process of contract development and manufacturing companies to develop P-Esbp-DOX for use in a first in-human clinical trial.

Last year, Vaxil conducted an initial in vivo oral vaccine study for a COVID-19 signal peptide-derived product. Following the identification of an initial signal, Vaxil decided to try to transition from the ImMucin (MUC1 signal peptide-derived product) injectable platform to an oral delivery platform. An ImMucin oral formulation was developed, and an in vivo study was performed aimed at testing the ImMucin oral formulation to induce a systemic immune response in mice. The results, have been inconclusive, and Vaxil will not pursue this.

Vaxil is also exploring the value in conducting experiments of the oral formulation of the potential COVID-19 vaccine candidate in combination with mRNA vaccines to boost T-cell protection to future variants.

<< Previous

Bullboard Posts

Next >>

Canopy Growth prepares for U.S. expansion with new acquisitions